secwatch.observer — SEC 8-K summary
======================================

Issuer:     enVVeno Medical Corp (NVNO)
CIK:        0001661053
Form:       8-K
Filed at:   2021-09-08T23:59:59+00:00
Accession:  0001493152-21-022214
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hancock Jaffe raises $20M in registered direct offering with Perceptive Advisors
--------------------------------------------------------------------------------

- Gross proceeds of $20M from sale of 781,615 shares at $7.872/share and pre-funded warrants for 1,759,035 shares at $0.0001 exercise.
- Net proceeds approximately $18.2M after placement agent fees (8% cash fee plus warrants) and expenses.
- Proceeds to be used for general corporate purposes and clinical development of the VenoValve.
- Company prohibited from issuing common stock or equivalents for 50 days post-closing; variable rate transactions banned for 6 months.
- Closing expected on or about September 9, 2021; Ladenburg Thalmann acting as exclusive placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661053/000149315221022214/0001493152-21-022214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661053/000149315221022214/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-022214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer